Skip to main content
. 2014 Nov 25;6(2):1008–1019. doi: 10.18632/oncotarget.2826

Figure 3. Autocrine SDF-1-CXCR4 signaling maintains a slow-cycling state and drug resistance in BM-derived DTCs.

Figure 3

(A) mRNA expression of CXCR4 (left) and SDF-1 (middle), and CXCR4 protein expression (right) in the P-HEp3 (P), Lu-HEp3 (Lu), and BM-HEp3 (BM) sublines, cultured in serum-free medium for 24 hours, was determined via qRT-PCR and Western blotting, respectively. *P < .001. n.s., not significant. (B) BM-HEp3 cells were treated with AMD3100 (5 μM) for 24 hours, after which SDF-1 mRNA expression was determined via qRT-PCR. †P < .05. (C) The sublines were treated with AMD3100 (5 μM) for 24 hours, after which cell numbers were counted. †P < .05. (D) Cells were treated with cisplatin (5 μg/ml) with or without AMD3100 (5 μM) for 48 hours, after which cell numbers were counted. Results are expressed as a percentage relative to cells without cisplatin in each experimental group. †P < .05,§P < .01. n.s., not significant. Values are means ± SEM of triplicate samples.